Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
28.1 EUR | -1.06% | -1.06% | +22.17% |
Feb. 29 | Clínica Baviera, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | Clínica Baviera, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023 | CI |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 221 | 233.1 | 229.9 | 345.6 | 284.5 | 375 |
Enterprise Value (EV) 1 | 224.4 | 280.1 | 257.6 | 364.7 | 293.8 | 372.5 |
P/E ratio | 18.7 x | 18.2 x | 16.5 x | 12.6 x | 9.64 x | 10.4 x |
Yield | 4.28% | - | 3.91% | 4.86% | 7.45% | 6.83% |
Capitalization / Revenue | 2.02 x | 1.87 x | 1.87 x | 1.99 x | 1.43 x | 1.65 x |
EV / Revenue | 2.05 x | 2.25 x | 2.1 x | 2.11 x | 1.48 x | 1.64 x |
EV / EBITDA | 10.3 x | 8.94 x | 7.76 x | 6.84 x | 5.18 x | 5.6 x |
EV / FCF | 35.9 x | 17.1 x | 12 x | 11.5 x | 8.82 x | 13.9 x |
FCF Yield | 2.79% | 5.85% | 8.35% | 8.68% | 11.3% | 7.2% |
Price to Book | 7.75 x | 7.62 x | 5.17 x | 6.33 x | 4.22 x | 4.12 x |
Nbr of stocks (in thousands) | 16,306 | 16,302 | 16,303 | 16,302 | 16,303 | 16,303 |
Reference price 2 | 13.55 | 14.30 | 14.10 | 21.20 | 17.45 | 23.00 |
Announcement Date | 4/26/19 | 6/16/20 | 4/13/21 | 4/12/22 | 4/8/24 | 4/8/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 109.3 | 124.3 | 122.6 | 173.2 | 198.4 | 227.1 |
EBITDA 1 | 21.69 | 31.34 | 33.21 | 53.35 | 56.76 | 66.5 |
EBIT 1 | 16.98 | 18.32 | 19.83 | 39.46 | 41.96 | 50.04 |
Operating Margin | 15.54% | 14.73% | 16.17% | 22.78% | 21.14% | 22.04% |
Earnings before Tax (EBT) 1 | 16.81 | 17.79 | 20.19 | 38.9 | 40.68 | 49.65 |
Net income 1 | 11.83 | 12.79 | 13.94 | 27.39 | 29.52 | 35.97 |
Net margin | 10.82% | 10.29% | 11.37% | 15.81% | 14.87% | 15.84% |
EPS 2 | 0.7254 | 0.7848 | 0.8553 | 1.680 | 1.811 | 2.206 |
Free Cash Flow 1 | 6.253 | 16.38 | 21.5 | 31.68 | 33.33 | 26.81 |
FCF margin | 5.72% | 13.17% | 17.54% | 18.28% | 16.79% | 11.81% |
FCF Conversion (EBITDA) | 28.83% | 52.26% | 64.75% | 59.37% | 58.72% | 40.31% |
FCF Conversion (Net income) | 52.88% | 127.99% | 154.24% | 115.65% | 112.9% | 74.52% |
Dividend per Share 2 | 0.5800 | - | 0.5520 | 1.030 | 1.300 | 1.570 |
Announcement Date | 4/26/19 | 6/16/20 | 4/13/21 | 4/12/22 | 4/8/24 | 4/8/24 |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 |
---|---|---|---|---|---|
Net sales 1 | 52.39 | 50.25 | 102.6 | 42.07 | 53.74 |
EBITDA 1 | 18.61 | 15.35 | 33.96 | 10.3 | 12.23 |
EBIT 1 | 15.03 | 11.59 | 26.62 | 6.5 | 8.375 |
Operating Margin | 28.69% | 23.06% | 25.93% | 15.45% | 15.58% |
Earnings before Tax (EBT) 1 | 14.92 | 11.49 | 26.42 | 6.365 | 7.899 |
Net income 1 | 11.11 | 8.455 | 19.56 | 4.606 | 5.351 |
Net margin | 21.2% | 16.83% | 19.06% | 10.95% | 9.96% |
EPS | - | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 5/17/22 | 7/26/22 | 7/26/22 | 11/16/22 | 2/28/23 |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | 3.42 | 47 | 27.8 | 19.1 | 9.31 | - |
Net Cash position 1 | - | - | - | - | - | 2.49 |
Leverage (Debt/EBITDA) | 0.1576 x | 1.499 x | 0.8358 x | 0.3586 x | 0.164 x | - |
Free Cash Flow 1 | 6.25 | 16.4 | 21.5 | 31.7 | 33.3 | 26.8 |
ROE (net income / shareholders' equity) | 44.4% | 43.3% | 37.3% | 55.7% | 48.7% | 45.7% |
ROA (Net income/ Total Assets) | 19.3% | 14.5% | 11.1% | 19.4% | 18.5% | 19% |
Assets 1 | 61.18 | 87.95 | 125.1 | 141.4 | 159.8 | 189.1 |
Book Value Per Share 2 | 1.750 | 1.880 | 2.730 | 3.350 | 4.130 | 5.580 |
Cash Flow per Share 2 | 0.2400 | 0.2400 | 0.6600 | 0.6000 | 1.180 | 0.5100 |
Capex 1 | 9.18 | 9.19 | 7.82 | 10.6 | 14 | 22.7 |
Capex / Sales | 8.4% | 7.39% | 6.38% | 6.1% | 7.07% | 9.99% |
Announcement Date | 4/26/19 | 6/16/20 | 4/13/21 | 4/12/22 | 4/8/24 | 4/8/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+22.17% | 489M | |
-20.16% | 16.21B | |
+4.50% | 12.44B | |
+3.98% | 11.58B | |
+9.72% | 10.79B | |
+23.61% | 8.26B | |
-2.19% | 7.68B | |
+20.75% | 7.2B | |
+4.49% | 6.67B | |
+50.89% | 4.66B |
- Stock Market
- Equities
- CBAV Stock
- Financials Clínica Baviera, S.A.